# Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

> **NCT01270503** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 538 (actual)

## Conditions studied

- Meningitis
- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- **BIOLOGICAL:** Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- **BIOLOGICAL:** Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

## Key facts

- **NCT ID:** NCT01270503
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-07
- **Target enrollment:** 538 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01270503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01270503, "Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01270503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*